Synthetic Biologics, Inc.
9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850
|May 14, 2018|
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Dorrie Yale
|Re:||Synthetic Biologics, Inc.|
Registration Statement on Form S-3
File No: 333-224728
Ladies and Gentlemen:
Synthetic Biologics, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-22478), to become effective on Tuesday, May 15, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.
|Very truly yours,|
|Synthetic Biologics, Inc.|
|By: /s/ Steven A. Shallcross|
|Name:||Steven A. Shallcross|
Interim Chief Executive Officer and
Chief Financial Officer
|cc:||Leslie Marlow, Esq., Gracin & Marlow, LLP|